-$0.05 Earnings Per Share Expected for Intec Pharma Ltd (NASDAQ:NTEC) This Quarter
Equities research analysts expect Intec Pharma Ltd (NASDAQ:NTEC) to report earnings of ($0.05) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Intec Pharma’s earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at ($0.04). Intec Pharma posted earnings per share of ($0.32) during the same quarter last year, which indicates a positive year-over-year growth rate of 84.4%. The business is expected to issue its next quarterly earnings results on Tuesday, November 10th.
On average, analysts expect that Intec Pharma will report full-year earnings of ($0.21) per share for the current year, with EPS estimates ranging from ($0.22) to ($0.20). For the next financial year, analysts expect that the company will report earnings of ($0.13) per share, with EPS estimates ranging from ($0.15) to ($0.12). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Intec Pharma.
Intec Pharma (NASDAQ:NTEC) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported ($0.05) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.05).
Shares of NASDAQ NTEC traded up $0.01 during midday trading on Tuesday, hitting $0.25. 2,100,954 shares of the company’s stock traded hands, compared to its average volume of 5,671,154. Intec Pharma has a 1 year low of $0.13 and a 1 year high of $0.79. The stock has a market capitalization of $18.03 million, a price-to-earnings ratio of -0.27 and a beta of 0.85. The firm has a fifty day moving average of $0.27 and a 200 day moving average of $0.30.
Large investors have recently made changes to their positions in the stock. Two Sigma Advisers LP grew its stake in shares of Intec Pharma by 326.1% during the 2nd quarter. Two Sigma Advisers LP now owns 88,200 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 67,500 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Intec Pharma during the 2nd quarter valued at approximately $29,000. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Intec Pharma by 61,948.1% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 367,325 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 366,733 shares during the period. Phoenix Holdings Ltd. grew its stake in shares of Intec Pharma by 315.9% during the 1st quarter. Phoenix Holdings Ltd. now owns 600,706 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 456,255 shares during the period. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Intec Pharma during the 2nd quarter valued at approximately $117,000. Institutional investors own 10.00% of the company’s stock.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Further Reading: What is a dead cat bounce?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.